Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06421675
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-20
First Post:
2024-03-11
Brief Title:
Outpatient and Intermittent Dosing of Elranatamab in RelapsedRefractory Multiple Myeloma
Sponsor:
Ontario Clinical Oncology Group OCOG
Organization:
Ontario Clinical Oncology Group OCOG
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-11
First Submit QC Date:
May 14 2024
Study First Post Date:
2024-05-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-16
Last Update Post Date:
2024-05-20
Last Update Post Date Type:
ACTUAL